
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
Betsy Goodfellow | February 21, 2024 | News story | Research and Development | Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and rilpivirine), a long-acting injectable antiretroviral treatment (ART) for HIV treatment.
The drug demonstrated a superior efficacy in maintaining viral load suppression compared to daily oral therapy in patients with a history of ART adherence challenges.
The trial is ongoing, however the DSMB has undertaken this planned interim review, which concluded that the long-acting ART demonstrated superior efficacy over daily oral standard of care, and recommended that all eligible trial participants should be offered the cabotegravir and rilpivirine treatment.
Kimberly Smith MD MPH, head of research and development at ViiV Healthcare, commented: “The interim data indicating the superiority of long-acting therapy compared to daily oral therapy in individuals who have difficulty taking pills for HIV every day is a remarkable outcome. There are many reasons why people may find it challenging to stay on daily oral treatment and the LATITUDE study shows cabotegravir and rilpivirine injectable treatment can help them keep their virus suppressed, which benefits their overall health. Optimising therapy for all people living with HIV, including those with adherence challenges, is critical to the effort to end the HIV epidemic.”
Betsy Goodfellow
Related Content

SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …




